Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Ablating UNG activity in a mouse model inhibits colorectal cancer growth by increasing tumor immunogenicity
Eric S. Christenson, Brandon E. Smith, Thanh J. Nguyen, Alens Valentin, Soren Charmsaz, Nicole E. Gross, Sarah M. Shin, Alexei Hernandez, Won Jin Ho, Srinivasan Yegnasubramanian, James T. Stivers
Eric S. Christenson, Brandon E. Smith, Thanh J. Nguyen, Alens Valentin, Soren Charmsaz, Nicole E. Gross, Sarah M. Shin, Alexei Hernandez, Won Jin Ho, Srinivasan Yegnasubramanian, James T. Stivers
View: Text | PDF
Research Article Genetics Immunology Oncology

Ablating UNG activity in a mouse model inhibits colorectal cancer growth by increasing tumor immunogenicity

  • Text
  • PDF
Abstract

Uracil DNA glycosylase (UNG) excises uracil and 5-fluorouracil bases from DNA and is implicated in fluorodeoxyuridine (FdU) resistance. Here we explore the effects of inhibiting UNG activity, or depleting the UNG protein, in 2 mouse syngeneic models for colorectal cancer. Overexpressing the small UNG inhibitor protein (UGI) in mismatch repair–deficient (MMR-deficient) MC38 cells injected into C57BL/6J mice delayed tumor growth and prolonged survival when combined with FdU. Combining UNG inhibition with FdU numerically increased CD4+ T lymphocytes and B cells compared with FdU or UNG inhibition alone, suggesting an immune component to the effects. In contrast, shRNA depletion of UNG in the absence of FdU treatment resulted in 70% of mice clearing their tumors, and a 3-fold increase in overall survival compared with FdU. Analysis of MC38 tumor–infiltrating immune cells showed UNG depletion increased monocyte and dendritic cell populations, with CD8+ T cells also numerically increased. shRNA depletion of UNG in MMR-proficient CT-26 cells injected into BALB/c mice produced minimal benefit; the addition of anti–PD-1 antibody synergized with UNG depletion to increase survival. Cytotoxic T cell depletion abolished the benefits of UNG depletion in both models. These findings suggest UNG inhibition and/or depletion could enhance antitumor immune responses in humans.

Authors

Eric S. Christenson, Brandon E. Smith, Thanh J. Nguyen, Alens Valentin, Soren Charmsaz, Nicole E. Gross, Sarah M. Shin, Alexei Hernandez, Won Jin Ho, Srinivasan Yegnasubramanian, James T. Stivers

×

Figure 7

Depletion of CD8+ T lymphocytes ablates the tumor growth and survival benefits of UNG depletion in MC38 tumor–bearing mice in the absence of FdU.

Options: View larger image (or click on image) Download as PowerPoint
Depletion of CD8+ T lymphocytes ablates the tumor growth and survival be...
C57BL/6J mice were treated with anti-CD8 depletion antibodies twice weekly to interrogate the contribution of CD8+ lymphocytes to the tumor clearance observed with UNG knockdown. Female C57BL/6J mice were injected with 2.5 × 105 MC38 cells containing either shRNAUNG or shRNActrl. The CD8+ cell depletion experiment was performed twice with 5 mice per experimental group. These panels show the combined data from both experiments: (a) shRNActrl without CD8+ cell depletion (shRNActrl CD8proficient), (b) shRNActrl with CD8+ cell depletion (shRNActrl CD8depleted), (c) shRNAUNG without CD8+ cell depletion (shRNAUNG CD8proficient), and (d) shRNAUNG with CD8+ cell depletion (shRNAUNG CD8depleted). (A) Tumor volumes for the 4 experimental groups were measured on the indicated days. Error bars for tumor growth are SEM. Tumor growth curves were compared using an unpaired 2-tailed t test. For shRNAUNG CD8proficient tumors, there was significantly reduced tumor growth as compared with both CD8depleted groups (P = 0.007). (B) Kaplan-Meier survival analysis for the 4 experimental groups. For shRNAUNG CD8proficient tumors, there was significantly improved survival in the UNG-depleted group as compared with both CD8depleted groups (P = 0.003, log-rank Mantel-Cox test). Seven of the mice in the shRNAUNG CD8proficient group cleared their tumors.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts